N18.3

Chronic kidney disease, stage 3 moderate

## Overview of Chronic Kidney Disease, Stage 3 Moderate (N18.3) Chronic Kidney Disease (CKD) stage 3, coded as N18.3, represents a moderate decline in kidney function. This stage is further divided into two sub-stages based on the estimated glomerular filtration rate (eGFR): * **Stage 3a:** eGFR between 45 and 59 mL/min/1.73m² * **Stage 3b:** eGFR between 30 and 44 mL/min/1.73m² At this stage, the kidneys are still functioning, but their ability to filter waste products from the blood and maintain fluid and electrolyte balance is significantly impaired compared to normal kidney function. Patients in CKD stage 3 have an increased risk of developing complications associated with kidney dysfunction, and the progression to more advanced stages (4 and 5) is a significant concern. ### Clinical Significance Individuals with CKD stage 3 often begin to experience symptoms related to reduced kidney function, although many may remain asymptomatic, especially in stage 3a. The moderate reduction in GFR can lead to: * **Accumulation of waste products:** Uremia may start to manifest, leading to fatigue, nausea, and loss of appetite. * **Anemia:** Decreased production of erythropoietin by the kidneys often leads to normochromic, normocytic anemia. * **Bone and mineral disorders:** Disruptions in calcium, phosphate, and vitamin D metabolism can result in secondary hyperparathyroidism and renal osteodystrophy. * **Cardiovascular disease:** CKD stage 3 is an independent risk factor for cardiovascular events, including heart attack, stroke, and heart failure. * **Electrolyte imbalances:** Hyperkalemia, hyperphosphatemia, and metabolic acidosis can develop. ### Management Goals Management for CKD stage 3 focuses on slowing the progression of kidney disease, managing complications, and preparing the patient for potential future kidney replacement therapies. Key aspects include: * **Blood pressure control:** Aiming for target blood pressure, often with ACE inhibitors or ARBs, to reduce proteinuria and protect kidney function. * **Glycemic control:** Strict management of blood sugar in diabetic patients. * **Dietary modifications:** Limiting protein, sodium, potassium, and phosphorus intake as guided by a dietitian. * **Anemia management:** Iron supplementation or erythropoiesis-stimulating agents. * **Bone and mineral management:** Phosphate binders and vitamin D analogues. * **Avoidance of nephrotoxic drugs:** Including NSAIDs and certain contrast agents. Regular monitoring of eGFR, proteinuria, blood pressure, electrolytes, and other relevant labs is crucial for effective management and timely intervention.

Clinical Symptoms

Fatigue and weakness
Swelling (edema) in legs, feet, or ankles
Muscle cramps
Nausea and loss of appetite
Itching (pruritus)
Changes in urination (e.g., increased frequency, especially at night)
Difficulty concentrating or mental fogginess
Shortness of breath (due to fluid overload or anemia)
Insomnia or sleep disturbances
Dry skin

Common Causes

Diabetes mellitus (type 1 and type 2)
Hypertension (high blood pressure)
Glomerulonephritis (inflammation of the kidney's filtering units)
Polycystic kidney disease (PKD)
Obstructive nephropathy (e.g., kidney stones, enlarged prostate, tumors blocking urine flow)
Recurrent kidney infections (pyelonephritis)
Autoimmune diseases (e.g., lupus nephritis, vasculitis)
Long-term use of certain medications (e.g., NSAIDs, some antibiotics)
Atherosclerosis leading to renal artery stenosis
Chronic exposure to toxins or heavy metals

Documentation & Coding Tips

Document the specific stage of Chronic Kidney Disease (CKD) and its underlying etiology clearly. Include relevant lab values like eGFR and proteinuria/albuminuria to support the diagnosis and staging.

Example: PATIENT: 68 y.o. male with T2DM (E11.22) and essential hypertension (I10) for routine follow-up. Current eGFR 42 mL/min/1.73m^2 (CKD-EPI, baseline 3 months prior: 45 mL/min/1.73m^2). Urine albumin-creatinine ratio (UACR) 150 mg/g. Dx: Chronic kidney disease, stage 3b moderate (N18.3), secondary to diabetic nephropathy (E11.22, N08) and hypertensive nephrosclerosis (I12.9). Patient is stable, denying acute symptoms. Plan: Continue Lisinopril 20mg daily, initiate Finerenone 10mg daily. Continue Metformin. Refer to nephrology for co-management. Discussed dietary modifications and fluid intake. Next F/U in 3 months.

Billing Focus: Explicitly states 'stage 3b moderate' (N18.3) and links to 'diabetic nephropathy' (E11.22, N08) and 'hypertensive nephrosclerosis' (I12.9), providing detailed specificity for accurate coding. Inclusion of eGFR and UACR objectively supports the stage. Precise identification of the specific etiologies justifies comprehensive management and medical necessity.

Identify and document all active complications and comorbidities related to CKD. Provide objective evidence (labs, physical exam findings) and detail management plans for each.

Example: PATIENT: 62 y.o. female with known CKD stage 3b (N18.3) secondary to uncontrolled hypertension (I10). Presenting with increased fatigue and leg swelling. Labs reveal Hgb 9.8 g/dL (previous 10.5 g/dL) (Dx: Anemia in chronic kidney disease, D63.1) and serum potassium 5.4 mEq/L (Dx: Hyperkalemia, E87.5). Lower extremity pitting edema 2+. Medications reviewed: Discontinued Spironolactone due to hyperkalemia, initiated Ferrous Sulfate 325mg PO daily. Increased Furosemide to 40mg BID. Discussed dietary potassium restriction and fluid intake. Recheck labs in 1 week. This visit involved moderate complexity medical decision making due to new onset anemia and hyperkalemia management.

Billing Focus: Specific coding for complications 'Anemia in chronic kidney disease' (D63.1) and 'Hyperkalemia' (E87.5) as distinct, actively managed problems. Objective findings (Hgb, K+ levels, edema) and detailed management changes (medication adjustments) support the medical necessity and higher E/M level for this complex visit, allowing for appropriate billing beyond just the CKD follow-up.

Accurately differentiate between Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD), and document 'Acute Kidney Injury on Chronic Kidney Disease' when appropriate, providing baseline and current renal function parameters.

Example: PATIENT: 75 y.o. male with known CKD Stage 3b (N18.3) secondary to benign prostatic hyperplasia (N40.1) admitted for acute urinary retention. Cr 2.5 mg/dL on admission (baseline Cr 1.6 mg/dL from 3 months prior). After Foley catheter placement, Cr improved to 1.8 mg/dL over 48 hours. Dx: Acute kidney injury (N17.9) superimposed on established chronic kidney disease, stage 3b (N18.3). Etiology of AKI is post-renal obstruction due to BPH. Patient responding well to treatment. Plan: Continue Foley for 72 hours, monitor renal function, consult Urology for BPH management. Discharged to home with follow-up. Medical decision making for this inpatient stay was high complexity.

Billing Focus: Clear distinction between 'Acute kidney injury' (N17.9) and the underlying 'Chronic kidney disease, stage 3b' (N18.3), explicitly stating 'superimposed'. Providing both baseline and acute creatinine levels objectively supports the AKI diagnosis. Identifying the etiology of AKI (post-renal obstruction/BPH) further enhances coding accuracy and medical necessity for specific interventions and consultations.

Relevant CPT Codes

99214 - Office or other outpatient visit, established patient
Used for established patients with CKD Stage 3 for comprehensive follow-up, involving medication adjustments, review of multiple lab results (GFR, electrolytes, CBC), assessment of comorbidities, and patient education on disease progression. The complexity of managing CKD with potential complications typically meets the criteria for moderate complexity MDM.
99204 - Office or other outpatient visit, new patient
Appropriate for an initial consultation with a nephrologist for a new CKD Stage 3 patient, requiring a thorough evaluation to establish diagnosis, etiology, severity, and to develop a comprehensive, individualized management plan. This often involves reviewing extensive prior records and multiple systems.
99215 - Office or other outpatient visit, established patient
Used by nephrologists for complex follow-up visits involving active management of progressive CKD, multiple uncontrolled complications (e.g., severe anemia, recurrent hyperkalemia, fluid overload), or decision-making regarding initiation of advanced therapies or preparation for end-stage renal disease.
82565 - Creatinine; blood
Essential for monitoring kidney function, calculating eGFR, and tracking CKD progression. Regular creatinine checks are fundamental to CKD management.
84156 - Protein, total; urine, quantitative
Monitoring proteinuria/albuminuria is crucial for assessing kidney damage, tracking CKD progression, and evaluating the effectiveness of renoprotective therapies.